
---
title: Multiple Myeloma & Amyloidosis (INICET High Yield)
markmap:
  colorFreezeLevel: 3
---

## Multiple Myeloma & Amyloidosis (INICET High Yield)

### Multiple Myeloma
- Definition
  - Plasma cell proliferative disorder
  - Malignant plasma cells in bone marrow
- Diagnosis
  - **CRAB Criteria** (End-organ damage)
    - Hyper**C**alcemia (>11 mg/dL)
    - **R**enal failure (Creatinine >2 mg/dL)
    - **A**nemia (Hb <10 g/dL or 2g below baseline)
    - **B**one lesions (Lytic lesions, pathological fractures)
  - **Myeloma Defining Events** (MDE)
    - Bone Marrow Plasma Cells >= 60%
    - Serum Free Light Chain Ratio >= 100 (involved/uninvolved)
    - >1 Focal Lesion on MRI (>= 5mm)
  - Investigations
    - **SPEP** (M-spike - IgG most common)
    - **IFE** (Confirm M-protein type)
    - **Serum Free Light Chains** (Kappa/Lambda ratio)
    - **Bone Marrow Biopsy** (>10% clonal plasma cells, CD138+)
    - Imaging (Skeletal survey, PET-CT, MRI Spine/Pelvis)
- Staging
  - **ISS** (International Staging System)
    - Serum Albumin
    - Serum Beta-2 Microglobulin
  - **R-ISS** (Revised ISS)
    - ISS stage + Cytogenetics (FISH) + LDH
- Clinical Features
  - Bone pain, Pathological fractures
  - Fatigue (Anemia)
  - Infections (Hypogammaglobulinemia)
  - Renal impairment
  - Neuropathy
  - Hyperviscosity syndrome (rare)
- Treatment
  - **Transplant Eligible**
    - Induction (e.g., VRD - Bortezomib, Lenalidomide, Dexamethasone)
    - Autologous Stem Cell Transplant (ASCT)
    - Maintenance (e.g., Lenalidomide)
  - **Transplant Ineligible**
    - Combination regimens (e.g., VRd, Daratumumab + Rd)
  - Relapsed/Refractory
    - Novel agents (Carfilzomib, Pomalidomide, Daratumumab, Isatuximab, Belantamab Mafodotin, Selinexor, CAR-T)
- Related Conditions
  - **MGUS** (Monoclonal Gammopathy of Undetermined Significance)
  - **Smoldering Multiple Myeloma** (SMM)

### Amyloidosis
- Definition
  - Extracellular deposition of misfolded proteins (amyloid fibrils)
- Types
  - **AL** (Light chain amyloidosis) - **Most common systemic**
    - Associated with plasma cell dyscrasias (MM, MGUS)
  - AA (Secondary)
    - Associated with chronic inflammation (RA, IBD, FMF)
    - Serum Amyloid A protein precursor
  - ATTR (Transthyretin)
    - Hereditary (Familial Amyloid Polyneuropathy/Cardiomyopathy)
    - Wild-type (Senile Systemic Amyloidosis)
  - Others (Aβ2m, Aβ, etc.)
- Diagnosis
  - Tissue Biopsy (Congo Red stain shows **Apple-green birefringence** under polarized light)
    - **Fat pad biopsy** (common site)
    - Rectal biopsy, Organ biopsy (Kidney, Heart)
  - Immunostaining/Mass Spectrometry to identify protein type
  - SPEP/IFE/SFLC (for AL type)
- Clinical Features (Organ involvement)
  - Kidney (**Nephrotic syndrome**, Proteinuria)
  - Heart (**Restrictive cardiomyopathy**, Arrhythmias)
  - Neuropathy (Sensory, Autonomic)
  - GI tract (Malabsorption, Bleeding)
  - Liver (Hepatomegaly)
  - Skin (**Periorbital purpura** - Raccoon eyes), easy bruising
  - Musculoskeletal (**Macroglossia**, Joint involvement)
- Treatment
  - Type-specific
  - **AL Amyloidosis:** Target underlying plasma cell dyscrasia (Chemotherapy - similar regimens to MM)

### Myeloma & AL Amyloidosis Link
- AL amyloidosis results from deposition of monoclonal light chains produced by clonal plasma cells.
- Can occur alongside overt MM, SMM, or MGUS.
- Management of AL amyloidosis involves treating the underlying plasma cell clone.

### INICET Buzzwords
- CRAB
- SPEP, IFE, SFLC, M-spike
- CD138+
- Rouleaux formation
- Lytic lesions
- ISS, R-ISS
- VRd, VTD, CyBorD
- Bortezomib (PI), Lenalidomide (IMiD), Thalidomide
- Daratumumab (CD38)
- Autologous SCT
- Congo Red, Apple-green birefringence
- Fat pad biopsy
- Macroglossia
- Periorbital purpura
- Restrictive cardiomyopathy
- Nephrotic syndrome
- Free light chains
